731 / 2894
14. McKenzie AG, Simpson KR: Current management
of patients taking herbal medicines: A survey of
anaesthetic practice in the UK. Eur J Anaesthesiol
22:597, 2005.
15. Kassler WJ, Blanc P, Greenblatt R: The use of
medicinal herbs by human immunodeficiency
virus–infected patients. Arch Intern Med 151:
2281, 1991.
16. Cirigliano M, Sun A: Advising patients about herbal
therapies. JAMA 280:1565, 1998.
17. Leak JA: Herbal medicines: What do we need to
know? ASA Newsl 64:6, 2000.
18. Kennedy JM,van Rij AM,Spears GF,et al: Polyphar-
macy in a general surgical unit and consequences
of drug withdrawal. Br J Clin Pharmacol 49:
353, 2000.
19. Tonnesen H, Rosenberg J, Nielsen HJ, et al: Effect of
preoperative abstinence on poor postoperative
outcome in alcohol misusers: Randomized contro-
lled trial. BMJ 318:1311, 1999.
20. Barrett BP, Brown RL, Locken K, et al: Treatment of
the common cold with unrefined echinacea. A ran-
domized, double-blind, placebo-controlled trial.
Ann Intern Med 137:939, 2002.
21. Shah SA, Sander S, White CM, et al: Evaluation of
echinacea for the prevention and treatment of the
common cold: A meta-analysis. Lancet Infect Dis
7:473, 2007.
22. Pepping J: Echinacea. Am J Health Syst Pharm
56:121, 1999.
23. Boullata JI, Nace AM: Safety issues with herbal
medicine. Pharmacotherapy 20:257, 2000.
24. Mullins RJ: Echinacea-associated anaphylaxis. Med
J Aust 168:170, 1998.
25. Miller LG: Herbal medicinals: Selected clinical con-
siderations focusing on known or potential
drug-herb interactions. Arch Intern Med 158:
2200, 1998.
26. Gurley BJ, Gardner SF, Hubbard MA: Content versus
label claims in ephedra-containing dietary supple-
ments. Am J Health Syst Pharm 57:963, 2000.
27. Nightingale SL: From the Food and Drug Adminis-
tration. JAMA 278:15, 1997.
28. Haller CA, Benowitz NL: Adverse cardiovascular
and central nervous system events associated with
dietary supplements containing ephedra alkaloids.
N Engl J Med 343:1833, 2000.
29. Zaacks SM, Klein L, Tan CD, et al: Hypersensitivity
myocarditis associated with ephedra use. J Toxicol
Clin Toxicol 37:485, 1999.
30. Powell T, Hsu FF, Turk J, Hruska K: Ma-huang
strikes again: Ephedrine nephrolithiasis. Am J
Kidney Dis 32:153, 1998.
31. White LM, Gardner SF, Gurley BJ, et al: Pharmaco-
kinetics and cardiovascular effects of ma-huang
(
Ephedra sinica
) in normotensive adults. J Clin
Pharmacol 37:116, 1997.
32. Gurley BJ, Gardner SF, White LM, Wang PL: Ephe-
drine pharmacokinetics after the ingestion of nutri-
tional supplements containing
Ephedra sinica
(ma
huang). Ther Drug Monit 20:439, 1998.
33. Stevinson C, Pittler MH, Ernst E: Garlic for treating
hypercholesterolemia: A meta-analysis of randomi-
zed clinical trials. Ann Intern Med 133:420, 2000.
34. Srivastava KC: Evidence for the mechanism by
which garlic inhibits platelet aggregation. Prosta-
glandins Leukoc Med 22:313, 1986.
35. Rose KD, Croissant PD, Parliament CF, Levin MB:
Spontaneous spinal epidural hematoma with associa-
ted platelet dysfunction from excessive garlic inges-
tion: A case report. Neurosurgery 26:880, 1990.
36. Silagy CA, Neil HA: A meta-analysis of the effect of
garlic on blood pressure. J Hypertens 12:463, 1994.
37. Le Bars PL, Katz MM, Berman N, et al: A placebo-
controlled, double-blind, randomized trial of an
extract of
Ginkgo biloba
for dementia. North
American Egb Study Group. JAMA 278:1327,
1997.
38. Solomon PR, Adams F, Silver A, et al: Ginko for
memory enhancement: A randomized controlled
trial. JAMA 288:835, 2000.
39. Rowin J, Lewis SL: Spontaneous bilateral subdural
hematomas associated with chronic
Ginkgo biloba
ingestion. Neurology 46:1775, 1996.
40. Vale S: Subarachnoid haemorrhage associated with
Ginkgo biloba
. Lancet 352:36, 1998.
41. Gilbert GJ: Ginkgo biloba. Neurology 48:1137,
1997.
42. Matthews MK Jr: Association of
Ginkgo biloba
with
intracerebral hemorrhage. Neurology 50:1933,
1998.
43. Rosenblatt M, Mindel J: Spontaneous hyphema
associated with ingestion of
Ginkgo biloba
extract.
N Engl J Med 336:1108, 1997.
44. Fessenden JM, Wittenborn W, Clarke L:
Ginkgo
biloba
: A case report of herbal medicine and blee-
ding postoperatively from a laparoscopic cholecys-
tectomy. Am Surg 67:33, 2001.
45. Watson DG, Oliveira EJ: Solid-phase extraction and
gas chromatography–mass spectrometry determina-
tion of kaempferol and quercetin in human urine
after consumption of
Ginkgo biloba
tablets. J Chro-
matogr B Biomed Sci Appl 723:203, 1999.
46. Mills S, Bone K: Ginkgo (eds.). In Mills S, Bone K
(eds): Principles and Practice of Phytotherapy.
New York, Churchill Livingstone, 2000, pp
404–417.
47. Brekham II, Dardymov IV: New substances of plant
origin which increase nonspecific resistance. Annu
Rev Pharmacol 9:419, 1969.
48. Soori GS, Bauer B, Sloan J, et al: A pilot, multi-dose,
placebo-controlled evaluation of American ginseng
(
Panax quinquefolius
) to improve cancer-related
fatigue: NCCTG trial N03CA. J Clin Oncol
25:493S, 2007.
49. Attele AS,Wu JA,Yuan CS: Ginseng pharmacology:
Multiple constituents andmultiple actions.Biochem
Pharmacol 58:1685, 1999.
50. Vuksan V, Sievenpiper JL, Koo VY, et al: American
ginseng (
Panax quinquefolius
L) reduces postpran-
dial glycemia in nondiabetic subjects and subjects
with type 2 diabetes mellitus. Arch Intern Med
160:1009, 2000.
51. Kimura Y, Okuda H, Arichi S: Effects of various
ginseng saponins on 5-hydroxytryptamine release
and aggregation in human platelets. J Pharm Phar-
macol 40:838, 1988.
52. Kuo SC, Teng CM, Lee JC, et al: Antiplatelet compo-
nents in
Panax ginseng
. Planta Med 56:164, 1990.
53. Park HJ, Lee JH, Song YB, Park KH: Effects of
dietary supplementation of lipophilic fraction from
Panax ginseng
on cGMP and cAMP in rat platelets
and on blood coagulation. Biol Pharm Bull 19:
1434, 1996.
54. Teng CM, Kuo SC, Ko FN, et al: Antiplatelet
actions of panaxynol and ginsenosides isolated
from ginseng. Biochim Biophys Acta 990:315,
1989.
55. Janetzky K, Morreale AP: Probable interaction
between warfarin and ginseng. Am J Health Syst
Pharm 54:692, 1997.
56. Yuan CS, Wei G, Dey L: American ginseng reduces
warfarin’s effect in healthy patients: A randomized,
controlled trial. Ann Intern Med 141:23, 2004.
57. Chen SE, Sawchuk RJ, Staba EJ: American ginseng.
III. Pharmacokinetics of ginsenosides in the
rabbit. Eur J Drug Metab Pharmacokinet 5:
161, 1980.
58. Pepping J: Kava:
Piper methysticum
. Am J Health
Syst Pharm 56:957, 1999.
59. Jamieson DD, Duffield PH, Cheng D, Duffield AM:
Comparison of the central nervous system activity
of the aqueous and lipid extract of kava (
Piper
methysticum
). Arch Int Pharmacodyn Ther 301:66,
1989.
60. Almeida JC, Grimsley EW: Coma from the health
food store: Interaction between kava and alprazo-
lam. Ann Intern Med 125:940, 1996.
61. Brown AC, Onopa J, Holck P, et al: Traditional kava
beverage consumption and liver function tests in a
predominantly Tongan population in Hawaii. Clin
Toxicol (Phila) 45:549, 2007.
62. Norton SA, Ruze P: Kava dermopathy. J Am Acad
Dermatol 31:89, 1994.
63. Rasmussen AK, Scheline RR, Solheim E, Hansel R:
Metabolism of some kava pyrones in the rat. Xeno-
biotica 9:1, 1979.
64. Bent S, Kane C, Shinohara K, et al: Saw palmetto for
benign prostatic hyperplasia. N Engl J Med 354:557,
2006.
65. Gerber GS: Saw palmetto for the treatment of men
with lower urinary tract symptoms. J Urol 163:1408,
2000.
66. Cheema P, El-Mefty O, Jazieh AR: Intraoperative
haemorrhage associated with the use of extract of
saw palmetto herb: A case report and review of
literature. J Intern Med 250:167, 2001.
67. Shelton RC, Keller MB, Gelenberg A, et al: Effecti-
veness of St. John’s wort in major depression. JAMA
285:1978, 2001.
68. Muller WE, Singer A, Wonnemann M, et al: Hyper-
forin represents the neurotransmitter reuptake
inhibiting constituent of
Hypericum
extract. Phar-
macopsychiatry 31:16, 1998.
69. Neary JT, Bu Y:
Hypericum
LI 160 inhibits uptake of
serotonin and norepinephrine in astrocytes. Brain
Res 816:358, 1999.
70. Brown TM: Acute St. John’s wort toxicity. Am J
Emerg Med 18:231, 2000.
71. Muller WE, Rolli M, Schafer C, Hafner U: Effects of
Hypericum
extract (LI 160) in biochemical models
of antidepressant activity. Pharmacopsychiatry
30:102, 1997.
72. Ernst E: Second thoughts about safety of St. John’s
wort. Lancet 354:2014, 1999.
73. Piscitelli SC, Burstein AH, Chaitt D, et al: Indinavir
concentrations and St. John’s wort. Lancet 355:547,
2000.
74. Yue QY, Bergquist C, Gerden B: Safety of St. John’s
wort. Lancet 355:576, 2000.
75. Breidenbach T,Hoffmann MW,Becker T,et al: Drug
interaction of St. John’s wort with cyclosporin.
Lancet 355:1912, 2000.
76. Ruschitzka F, Meier PJ, Turina M, et al: Acute heart
transplant rejection due to Saint John’s wort. Lancet
355:548, 2000.
77. Johne A, Brockmoller J, Bauer S, et al: Pharmacoki-
netic interaction of digoxin with an herbal extract
from St. John’s wort (
Hypericum perforatum
). Clin
Pharmacol Ther 66:338, 1999.
78. Hu ZP,Yang XX, Chen X, et al: A mechanistic study
on altered pharmacokinetics of irinotecan by St.
John’s wort. Curr Drug Metab 8:157, 2007.
79. Kerb R, Brockmoller J, Staffeldt B, et al: Single-dose
and steady-state pharmacokinetics of hypericin and
pseudohypericin. Antimicrob Agents Chemother
40:2087, 1996.
80. Biber A, Fischer H, Romer A, Chatterjee SS: Oral
bioavailability of hyperforin from
Hypericum
Tratamientos complementarios y alternativos
731
22
Sección II
Farmacología y anestesia